Alicia Alford, a recent graduate of the BULLS Life Sciences Academy and Durham Technical Community College, said Accelerate ...

Novo Nordisk, which has long manufactured treatments for diabetes and obesity in Johnston and Durham counties ... Since 2020, Eli Lilly & Co. has committed at least $16 billion to develop new ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Eli Lilly recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and Kenneth Custer, marking a strategic shift aiming to expand its global market presence ...

Eli Lilly experienced an 11% share price increase over the past month, largely influenced by the affirmation of a $1.50 per share dividend declared for the second quarter. The announcement of Q1 ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the ...

Big move on Thursday as investors in Eli Lilly and Company (LLY) endured an almost 12% downside as investors consider the aftermath of the CVS formulary decision changes that impacted the ...

President Donald Trump signed a new executive order aimed at boosting domestic drug manufacturing. The executive order comes ahead of the Trump administration's planned tariffs on pharmaceuticals ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong pricing power, which enables the firm to generate ...